Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report.
So BJ, Bekaii-Saab T, Bloomston MA, Patel T.
The Ohio State University Medical Center, 395 W, 12th Avenue, Columbus, OH 43210, USA. tushar.patel@osumc.edu.
ABSTRACT: Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.
PMID: 18928548 [PubMed - in process]PMCID: PMC2575202